3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
49
Pancreatic Neoplasms
33
Prostatic Neoplasms
31
Brain Neoplasms
28
Lung Neoplasms
26
Neoplasm Metastasis
24
Melanoma
21
Carcinoma, Hepatocellular
20
Breast Neoplasms
16
Carcinoma, Renal Cell
12
Colorectal Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
10
Neoplasms
9
Small Cell Lung Carcinoma
7
Urinary Bladder Neoplasms
5
Recurrence
5
Head and Neck Neoplasms
5
Glioblastoma
5
Adenocarcinoma of Lung
5
Sarcoma
4
Liver Neoplasms
4
Kidney Neoplasms
4
Uterine Cervical Neoplasms
3
NSCLC
3
Clear-cell metastatic renal cell carcinoma
3
Cholangiocarcinoma
3
Uveal Melanoma
2
Unresectable Locally Recurrent Rectal Cancer
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Interventions
blinatumomab
9
Cyclophosphamide
7
Rituximab
6
Lenalidomide
6
Dexamethasone
5
Azacitidine
5
venetoclax
4
fludarabine
4
Cytarabine
4
fludarabine phosphate
3
Maintenance
3
Busulfan
3
tislelizumab
2
thymoglobulin
2
pembrolizumab
2
obinutuzumab
2
daratumumab
2
Whole-Body Irradiation
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Methotrexate
2
Melphalan
2
Immunotherapy
2
Imatinib Mesylate
2
Drug Therapy
2
Docetaxel
2
Decitabine
2
Clofarabine
2
Cladribine
2
Carboplatin
2
Calcium Dobesilate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm, Residual
×
Radiosurgery
×
Clear all
NCT04944173
2024-09-03
SCION
University of British Columbia
Phase 2
Withdrawn